Cargando…

Serum Procalcitonin in Patients With Combined Lung Cancer and Idiopathic Pulmonary Fibrosis (LC-IPF)

Background Procalcitonin (PCT) is a potential biomarker for sepsis and acts as a guide to antibiotic administration. Previous studies showed that lung cancer (LC) may increase serum PCT levels. However, no studies addressed serum PCT in patients with combined LC and idiopathic pulmonary fibrosis (IP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohamed, Sherif, Abdelhaffez, Azza, Abd El-Aziz, Nashwa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2020
Materias:	Pathology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458704/ https://www.ncbi.nlm.nih.gov/pubmed/32879828 http://dx.doi.org/10.7759/cureus.9507

Ejemplares similares

IPF - Idiopathic Pulmonary Fibrosis
Publicado: (2019)

Idiopathic Pulmonary Fibrosis (IPF): An Overview
por: Barratt, Shaney L., et al.
Publicado: (2018)

Incidence and pathophysiologic mechanisms of stroke in the COVID-19 pandemic: the dilemma
por: Mohamed, Sherif, et al.
Publicado: (2020)

Prevalence, risk factors, and impact of lung Cancer on outcomes of idiopathic pulmonary fibrosis: a study from the Middle East
por: Mohamed, Sherif, et al.
Publicado: (2018)

Colitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF)
por: Oda, Keishi, et al.
Publicado: (2017)

Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
por: Snyder, Laurie D, et al.
Publicado: (2020)

MiR-608 overexpression in idiopathic pulmonary fibrosis (IPF)
por: Epstein Shochet, Gali, et al.
Publicado: (2021)

Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry
por: Kim, Hyun J., et al.
Publicado: (2022)

Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry
por: Kaunisto, Jaana, et al.
Publicado: (2019)

Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)
por: Krauss, Ekaterina, et al.
Publicado: (2019)

Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry
por: O'Brien, Emily C, et al.
Publicado: (2016)

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
por: Behr, Jürgen, et al.
Publicado: (2015)

Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study
por: Leuschner, Gabriela, et al.
Publicado: (2020)

The transition from normal lung anatomy to minimal and established fibrosis in idiopathic pulmonary fibrosis (IPF)
por: Xu, Feng, et al.
Publicado: (2021)

Is it the time to implement the routine use of distress thermometer among Egyptian patients with newly diagnosed cancer?
por: Abd El-Aziz, Nashwa, et al.
Publicado: (2020)

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
por: Finnerty, James Patrick, et al.
Publicado: (2021)

HSP90 Inhibition and Modulation of the Proteome: Therapeutical Implications for Idiopathic Pulmonary Fibrosis (IPF)
por: Colunga Biancatelli, Ruben Manuel Luciano, et al.
Publicado: (2020)

Regeneration or Repair? The Role of Alveolar Epithelial Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF)
por: Confalonieri, Paola, et al.
Publicado: (2022)

Molecular Phenotypes Distinguish Patients with Relatively Stable from Progressive Idiopathic Pulmonary Fibrosis (IPF)
por: Boon, Kathy, et al.
Publicado: (2009)

Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry
por: Ferrara, Giovanni, et al.
Publicado: (2016)

IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe
por: Duck, Annette, et al.
Publicado: (2015)

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis
por: Guenther, Andreas, et al.
Publicado: (2018)

Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America
por: Cherrez-Ojeda, Iván, et al.
Publicado: (2018)

Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2019)

Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
por: Salisbury, Margaret L., et al.
Publicado: (2020)

Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
por: Todd, Jamie L., et al.
Publicado: (2019)

There is detectable variation in the lipidomic profile between stable and progressive patients with idiopathic pulmonary fibrosis (IPF)
por: Nambiar, Shabarinath, et al.
Publicado: (2021)

Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry
por: Swaminathan, Aparna C., et al.
Publicado: (2022)

Radiological Assessment in Idiopathic Pulmonary Fibrosis (IPF) Patients According to MUC5B Polymorphism
por: Cocconcelli, Elisabetta, et al.
Publicado: (2022)

Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
por: Win, Thida, et al.
Publicado: (2018)

The Potential Effects of Curcumin on Pulmonary Fibroblasts of Idiopathic Pulmonary Fibrosis (IPF)—Approaching with Next-Generation Sequencing and Bioinformatics
por: Chang, Wei-An, et al.
Publicado: (2020)

Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema
por: Zantah, Massa, et al.
Publicado: (2020)

Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia With Progression to Neuroendocrine Tumor
por: Sousa, Débora, et al.
Publicado: (2021)

Procalcitonin-Guided Antibiotic Use in Acute Exacerbations of Idiopathic Pulmonary Fibrosis
por: Ding, Juanjuan, et al.
Publicado: (2013)

Is COVID-19 Similar in Pregnant and Non-Pregnant Women?
por: Selim, Mohamed, et al.
Publicado: (2020)

The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF) - practical implications
por: Wells, Athol U
Publicado: (2013)

Effects of hypoxia and hyperoxia on the differential expression of VEGF-A isoforms and receptors in Idiopathic Pulmonary Fibrosis (IPF)
por: Barratt, Shaney L., et al.
Publicado: (2018)

Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry
por: Jo, Helen E., et al.
Publicado: (2018)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
por: Barratt, Shaney L., et al.
Publicado: (2018)

Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry
por: Kreuter, Michael, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6m69lobbv1vt7lbceuq9rnu65c